Search International and National Patent Collections
Some content of this application is unavailable at the moment.
If this situation persists, please contact us atFeedback&Contact
1. (WO2017111129) NOVEL GENETIC ABNORMALITY RELATED TO ACUTE LYMPHOBLASTIC LEUKEMIA, AND USES THEREOF
Latest bibliographic data on file with the International Bureau

Pub. No.: WO/2017/111129 International Application No.: PCT/JP2016/088570
Publication Date: 29.06.2017 International Filing Date: 22.12.2016
IPC:
C12Q 1/68 (2006.01) ,A61K 45/00 (2006.01) ,A61P 35/02 (2006.01) ,C07K 16/32 (2006.01) ,C07K 19/00 (2006.01) ,C12N 15/09 (2006.01)
C CHEMISTRY; METALLURGY
12
BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
Q
MEASURING OR TESTING PROCESSES INVOLVING ENZYMES OR MICRO-ORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
1
Measuring or testing processes involving enzymes or micro-organisms; Compositions therefor; Processes of preparing such compositions
68
involving nucleic acids
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
45
Medicinal preparations containing active ingredients not provided for in groups A61K31/-A61K41/132
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
P
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
35
Antineoplastic agents
02
specific for leukemia
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
K
PEPTIDES
16
Immunoglobulins, e.g. monoclonal or polyclonal antibodies
18
against material from animals or humans
32
against translation products from oncogenes
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
K
PEPTIDES
19
Hybrid peptides
C CHEMISTRY; METALLURGY
12
BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
N
MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15
Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09
Recombinant DNA-technology
Applicants:
国立大学法人名古屋大学 NATIONAL UNIVERSITY CORPORATION NAGOYA UNIVERSITY [JP/JP]; 愛知県名古屋市千種区不老町1番 1, Furo-cho, Chikusa-ku, Nagoya-shi, Aichi 4648601, JP
Inventors:
奥野 友介 OKUNO Yusuke; JP
小島 勢二 KOJIMA Seiji; JP
鈴木 喬悟 SUZUKI Kyogo; JP
川島 希 KAWASHIMA Nozomu; JP
関屋 由子 SEKIYA Yuko; JP
Agent:
萩野 幹治 HAGINO Mikiharu; JP
Priority Data:
2015-25517925.12.2015JP
Title (EN) NOVEL GENETIC ABNORMALITY RELATED TO ACUTE LYMPHOBLASTIC LEUKEMIA, AND USES THEREOF
(FR) NOUVELLE ANOMALIE GÉNÉTIQUE LIÉE À LA LEUCÉMIE AIGUË LYMPHOBLASTIQUE ET SON UTILISATION
(JA) 急性リンパ性白血病関連の新規遺伝学的異常及びその利用
Abstract:
(EN) The present invention addresses the problem of discovering a novel genetic abnormality, which is useful for the determination of treatment strategies or prognostic prediction of acute lymphoblastic leukemia, and contributing to the improvement of treatment outcomes. A genetic abnormality characterized by the formation of a fusion gene comprising the MEF2D gene and the BCL9 gene has been discovered from recurrent childhood acute lymphoblastic leukemia patients. This genetic abnormality will serve as a new indicator when determining treatment strategies.
(FR) La présente invention concerne une nouvelle anomalie génétique utile pour la détermination de stratégies thérapeutiques ou la prédiction pronostique de la leucémie aiguë lymphoblastique et contribuant à l'amélioration des résultats thérapeutiques. Une anomalie génétique caractérisée par la formation d'un gène de fusion comprenant le gène MEF2D et le gène BCL9 a été découverte chez des patients atteints de leucémie aiguë lymphoblastique récurrente infantile. Cette anomalie génétique servira de nouvel indicateur lors de la détermination des stratégies thérapeutiques.
(JA) 急性リンパ性白血病の治療方針の決定や予後予測などに役立つ、新規な遺伝学的異常を見出し、治療成績の向上に貢献することを課題とする。再発小児急性リンパ性白血病患者から、MEF2D遺伝子とBCL9遺伝子との融合遺伝子の形成で特徴付けられる遺伝学的異常が見出された。この遺伝学的異常は治療方針を決定する際の新たな指標となる。
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
African Regional Intellectual Property Organization (ARIPO) (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG)
Publication Language: Japanese (JA)
Filing Language: Japanese (JA)